SEPICALM TM VG C/3481/GB/01/FEBRUARY 2007 / 1
? 3 1. 2. 3. C/3481/GB/01/FEBRUARY 2007 / 2
SEPICALM VG INCI C/3481/GB/01/FEBRUARY 2007 / 3
1. C/3481/GB/01/FEBRUARY 2007 / 4
? SEPICALM VG 1 2 SEPICALM VG C/3481/GB/01/FEBRUARY 2007 / 5
SEPICALM VG? SEPICALM VG : SEPICALM VG SEPICALM VG SEPICALM VG (cox2) (PGE2) + => SEPICALM VG C/3481/GB/01/FEBRUARY 2007 / 6
1. 1.1 SEPICALM VG C/3481/GB/01/FEBRUARY 2007 / 7
1.? epidermis IL-1alpha 1 2 (cox2) 2 SEPICALM VG COX2 : cox2 ( % anti cyclooxy genase activity 60 40 20 0 46% SEPICALM VG 0,15% (am) 28% DiK+Glycyrrhizina 0,15% (am) => SEPICALM VG IL-1α 1? C/3481/GB/01/FEBRUARY 2007 / 8
2. IL-1α 1: ( 30 mj/cm2 UVB, SEPICALM VG) IL-1α 1: a. IL-1α : b. 1 : quantity of IL1 alpha in mg/ml 50 40 30 20 10 0-28%* quantity of endothelin e 1 in mg/ml 5 + Sepicalm VG 0 *p=0,07 UVB 0,00025% + *p<0,05 + UVB UVB 40 35 30 25 20 15 10-120%* Sepicalm VG 0,00025% + UVB 2 SEPICALM VG IL-1α 1 C/3481/GB/01/FEBRUARY 2007 / 9
3. ( 3D 7 ) : +3% SEPICALM VG 3D Skinethic TM ( IV) UVB 50 mj/cm2 UVA 1J/cm2 7. 7 : 35 microg/ml 30 25 20 15 10 *p<0,05 5 0-82%* + UV + 3% Sepicalm VG + UV SEPICALM VG (IL-1α, 1, 2) SEPICALM VG. C/3481/GB/01/FEBRUARY 2007 / 10
1. 1.2 SEPICALM VG C/3481/GB/01/FEBRUARY 2007 / 11
1. SEPICALM VG B16,, 72. a. : b. microg/ml 150 130 110 90 70 50 30-57%*** U/mg protein 70 60 50 40 30 20 10 0-54%*** 10 ***p<0,001-10 0,001% 0,001% Sepicalm VG 0,001% 0,001% 0,001% Sepicalm VG 0,001% SEPICALM VG. SEPICALM VG C/3481/GB/01/FEBRUARY 2007 / 12
2. 73D: +3% SEPICALM VG +3% Skinethic TM ( VI) 7 a. : b. : L* = a* = () microg/ml alone *p<0,05 200 150 100 50 0 +3% -31%* +3% Sepicalm VG % color variation /base alone *p<0,05 20 10 0-10 -20-1% L +18% a +3% b*= () +8% b +5% L -17%* a -10% b +3%Sepicalm VG SEPICALM VG ( L* a* b*) => C/3481/GB/01/FEBRUARY 2007 / 13
3. SEPICALM VG (DNA, 64 ) PCR a. +192%*** % ***p<0,001 150 50-50 MIC 1 MITF -41%*** -44%*** SEPICALM VG MIC1 MITF => C/3481/GB/01/FEBRUARY 2007 / 14
4. : 1 2 Conditions basales + SEPICALM VG /MIC1?? => Sepicalm VG : mitf mitf 1. Wnt β-catenin (MITF), => 2. Sepicalm VG MIC1 BMP Wnt )=> β catenin => MITF => => MITF Liu et al., 2006 Tyrosinase, Mc1r, Mart1,, Mitf, Rab27a, etc.. Tyrosinase, Mc1r, Mart1, Mitf etc. C/3481/GB/01/FEBRUARY 2007 / 15
1. 1.3 SEPICALM VG C/3481/GB/01/FEBRUARY 2007 / 16
1. - 3% SEPICALM VG ( 7057) - 30 - - 2 3 1. 2. 7057 : MONTANOV TM 68 (Cetearyl alcohol and Cetearyl glucoside - SEPPIC) 2.00 % MONTANOV TM 202 (Arachidyl alcohol and behenyl alcohol and 2.00 % arachidylglucoside - SEPPIC) LANOL TM P (glycol palmitate SEPPIC) 2.00 % LANOL TM 99 (isononyl isononanoate SEPPIC) 8.00 % Water Up to100% Chlorphenesin 0.30 % Magnesium aluminium silicate 1.00 % Cyclopentasiloxane 4.00 % SIMULGEL TM EG (Sodium acrylate/acryloyldimethyltaurate copolymer and 1.00 % Isohexadecane and Polysorbate 80 - SEPPIC) SEPICALM TM VG (Sodium palmitoyl proline & Nymphaea alba flower extract - 3.00 % SEPPIC) DL alpha tocopherol 0.05% Fragrance 0.30 % SEPICIDE TM HB (Phenoxyethanol & Methylparaben & Ethylparaben& 0.70 % Propylparaben & Butylparaben - SEPPIC) TEA 0.35 % C/3481/GB/01/FEBRUARY 2007 / 17
1. SEPICALM VG => ( 7057) 1.1 ( ITA) : 1.2 ( MI) : O ITA 2 1.8 1.6 1.4 1.2 1 0.8 0.6 0.4 0.2 0 64% ITA 2 * limit 67% ITA 3 ** O ITA MT = 100% 2 0-2 -4-6 -8-10 -12 67% * *** 2 3 79% ITA = ArcTg (L 50) X 180 b π *: p<0,05 **: p<0,01 ***: p<0,001, SEPICALM VG ( ITA ), C/3481/GB/01/FEBRUARY 2007 / 18
2. SEPICALM VG => ( 7057) ( ITA) 88% ITA 88% ITA 0ITA 4 3.5 3 2.5 2 1.5 1 0.5 0 2 *** *** 3 ***: p<0,001 0 ITA = 100%, SEPICALM VG ( ITA).. C/3481/GB/01/FEBRUARY 2007 / 19
3. 3 ( 7057) 90% 91% 94% 73% 96% 87% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% : 91% 7057, 77% C/3481/GB/01/FEBRUARY 2007 / 20
SEPICALM VG, 1 2 1 1 3 2 C/3481/GB/01/FEBRUARY 2007 / 21
2. C/3481/GB/01/FEBRUARY 2007 / 22
SEPICALM VG, SEPICALM VG SEPICALM VG (AHAs) SEPICALM VG SEPICALM VG 1%. (am) 1% SEPICALM VG (am) 0 0.5 1 2.5 5 min 0% 0 0 0 0 0-10% -20% -30% -40% -50% -60% -70% -47% -62% -46% -56% -25% -37% -45% -52% + 3% sepicalm VG + + % skin tem p eratu re d ecrease/ co n tro l ( C ) 0-0.1-0.2-0.3-0.4-0.5-0.6-0.7-0.8 NS NS - 0,8 C * C/3481/GB/01/FEBRUARY 2007 / 23
SEPICALM VG 3% :. 48. 3 2. (Marzulli Maibach protocol). ( ) : 3% C/3481/GB/01/FEBRUARY 2007 / 24
3. C/3481/GB/01/FEBRUARY 2007 / 25
: SEPICALM VG 3%.. => SEPIPLUS.. ph. : SEPICALM VG 40 C C/3481/GB/01/FEBRUARY 2007 / 26
7057 Formula A MONTANOV TM 68 (Cetearyl alcohol and Cetearyl glucoside - SEPPIC) 2.00 % MONTANOV TM 202 (Arachidyl alcohol and behenyl alcohol and 2.00 % arachidylglucoside - SEPPIC) LANOL TM P (glycol palmitate SEPPIC) 2.00 % LANOL TM 99 (isononyl isononanoate SEPPIC) 8.00 % B Water Up to100% Chlorphenesin 0.30 % Magnesium aluminium silicate 1.00 % C Cyclopentasiloxane 4.00 % SIMULGEL TM EG (Sodium acrylate/acryloyldimethyltaurate copolymer and 1.00 % Isohexadecane and Polysorbate 80 - SEPPIC) D SEPICALM TM VG (Sodium palmitoyl proline & Nymphaea alba flower extract - SEPPIC) 3.00 % E DL alpha tocopherol 0.05% Fragrance 0.30 % SEPICIDE TM HB (Phenoxyethanol & Methylparaben & Ethylparaben& 0.70 % Propylparaben & Butylparaben - SEPPIC) F TEA 0.35 % Procedure (TRIMIX 8 kg) Melt fatty components at 80 C ; Heat water in the main tank, then dissolve chlorphenesin (rotor stator 3000 rpm 5 ) and add magnesium aluminium silicate (planetary mixer + rotor stator 1000 rpm 10 ). Add the warm fatty phase and start homogenizing at 3000 rpm. After 5 allow to cool. Introduce the silicon at 65 C then SIMULGEL TM while keeping homogenization 5 more. Stop the rotor stator and cool to 60 C. Then add SEPICALM TM VG. At 30 C add ingredients in D ; If required adjust final ph. After 60 C all steps are conducted under vaccum. C/3481/GB/01/FEBRUARY 2007 / 27
4. SEPICALM VG C/3481/GB/01/FEBRUARY 2007 / 28
SEPICALM VG INCI C/3481/GB/01/FEBRUARY 2007 / 29
SEPICALM VG SEPICALM VG + SEPIWHITE MSH UVA / UVB SILASOME MEA : DNA Sepicalm VG Sepiwhite MSH UV C/3481/GB/01/FEBRUARY 2007 / 30
Nota The analytical specifications warranted are only those mentioned on the certificate of analysis supplied with each delivery of the product. Except as set forth above, SEPPIC* makes no warranties, whether express, implied or statutory, as to the product which is the subject of this document. Without limiting the generality of the foregoing, SEPPIC* makes no warranty of merchantability of the product or of the fitness of the product for any particular purpose. Buyer assumes all risk and liability resulting from the use or sale of the product, whether singly or in combination with other goods. The information set forth herein is furnished free of charge and is based on technical data that SEPPIC* believes to be reliable. It is intended for use by persons having technical skill and at their own discretion and risk. Since conditions of use are outside SEPPIC*'s control, SEPPIC* makes no warranties, express or implied, and assumes no liability in connection with any use of this information. Nothing herein is to be taken as a license to operate under or a recommendation to infringe any patents. * SEPPIC being: And, depending on the country: SEPPIC S.A. SEPPIC UK Ltd SEPPIC ITALIA Srl 75, quai d Orsay 50 Salisbury Road Via Quarenghi 27 75321 Paris cedex 07 PO Box 338 - Hounslow 20151 Milano FRANCE TW4 6SH - ENGLAND ITALY Tel. : +33 (0) 1 40 62 55 55 Tel. : +44 208 577 8800 Tel. : +39 02 38009110 Fax : +33 (0) 1 40 62 52 53 Fax : +44 208 570 2106 Fax : +39 02 38009140 GIVAUDAN LAVIROTTE S.A. SEPPIC Inc. SEPPIC Chine 56, rue Paul Cazeneuve 30, Two Bridges Road, suite 210 Room 510 Jin Tai Building BP 8344 69008 Lyon Fairfield, New Jersey 07004-1530 58 South Mao Ming Road FRANCE USA Shanghai 200020 CHINA Tel. : +33 (0) 4 78 61 55 00 Tel. : +1 973 882 5597 Tel. : +86 (21) 64 66 01 49 Fax : +33(0) 4 72 05 60 89 Fax : +1 973 882 5178 Fax : +86 (21) 64 66 11 09 SEPPIC GmbH SEPPIC Belgium NV ABC Tower Köln Nieuwe Weg 1 Ettore - Bugatti - Str.6-14 Haven 1053 51149 Köln-Porz B 2070 Zwijndrecht GERMANY BELGIUM Tel. : +49 (0) 220 3890 3100 Tel. : +32 3 250 3911 Fax : +49 (0) 220 3890 3199 Fax : +32 3 250 3912 www.seppic.com Subsidiary of the AIR LIQUIDE Group C/3481/GB/01/FEBRUARY 2007 / 31